Jeffrey Davis

Subscribe to Jeffrey Davis's Posts

Jeffrey is a skilled healthcare executive with substantial knowledge of regulatory advocacy and healthcare policies. Jeffrey’s work focuses on issues tied to provider payment and reimbursement as well as quality reporting. He also has significant experience with recent regulatory developments such as the implementation of surprise billing rules. Read Jeffrey Davis's full bio.

2024 Chart of Healthcare Regulations

By Kristen O'Brien, Rachel Stauffer, Katie Waldo and Jeffrey Davis on Apr 24, 2024
Posted In Employee Benefits, Health and Welfare Plans

During this election year, McDermottPlus is actively monitoring annual regulations that federal agencies are expected to release, as well as “ad hoc” regulations that will be released at the discretion of federal agencies. This chart displays health-related regulations that may be issued this year, organized by federal agency and date of potential release. Access the...

Continue Reading

Doctors Question Medicare Quality Program as More Face Steeper Penalties

By Jeffrey Davis on Nov 28, 2023
Posted In Employee Benefits, Health and Welfare Plans

A Medicare program designed to incentivize high-quality care via physician bonuses is in doubt as providers say it’s caused more trouble than it’s worth. According to this Axios article, the Merit-Based Incentive Payment System has created a disparity between bonus winners and losers, and this disparity is only expected to grow. Access the article.

Continue Reading

Surprise Billing Arbitration Is Still a Mess

By Jeffrey Davis on Nov 22, 2023
Posted In Employee Benefits, Health and Welfare Plans

Despite a two-year-old ban on surprise medical billing, insurers and providers are struggling to resolve unpaid claims. In this Axios article, McDermott+Consulting’s Jeffrey Davis offers perspective on the state of the claims resolution process. Read more here.

Continue Reading

Patients May Not Feel Benefits of Medicare Drug Price Negotiations

By Jeffrey Davis on Oct 4, 2023
Posted In Employee Benefits, Health and Welfare Plans, Uncategorized

The Biden administration recently announced a list of Medicare-covered drugs that will be subject to price negotiations. The administration said the negotiations—a reality thanks to the Inflation Reduction Act—will benefit nearly nine million seniors. However, according to this Insider article, some drug-policy analysts seem unconvinced by the administration’s claims. Access the article.

Continue Reading